Research Article

Decreased Apoptotic Rate of Alveolar Macrophages of Patients with Idiopathic Pulmonary Fibrosis

Table 5

Correlation of apoptotic markers’ expression with respiratory function parameters before and after treatment in patients with IPF.

Before treatmentFVC FVC%FEV1FEV1%FEV1/FVCDLCODLCO%aFVCaFVC%aFEV1aFEV1%aFEV1/FVCaDLCOaDLCO%

ApoptAg (+) cellsPearson ,010−,215,021−,190−,104,046,066−,060−,212−,027−,192,139−,219−,234
P,966,377,931,436,672,875,821,812,398,916,446,583,473,441
Apopt Ag areaPearson ,021−,206,046−,247,134−,377−,340−,069−,236−,002−,242,259−,300−,439
P,942,460,871,374,634,283,337,806,397,994,384,351,343,153
ApoptAg densityPearson −,052,177,019,240,427,042,188−,243−,187−,238−,330,348−,517−,538
P,854,529,947,390,113,908,602,383,504,393,230,204,086,071
Bcl-2 (+) cellsPearson ,388,168,365,082−,279,204,089,449,334,462,281−,387,557,451
P,091,479,113,730,233,466,751,054,162,046,245,102,039 ,106
Bcl-2 densityPearson −,196−,082−,215−,071,144−,086-,015−,058,075−,048,105,188−,439−,421
P,467,762,425,794,594,780,961,838,792,866,709,502,204,226
Bax (+) cellsPearson ,039−,199−,086−,314−,643,314,265,105−,021−,015−,125−,330−,066−,024
P,872,401,718,178,002,255,340,667,932,951,611,168,823,936
Bax densityPearson −,072−,257−,125−,379,269−,329−,247,183,109,198,060−,078−,435−,368
P,790,337,646,148,314,250,395,513,699,479,832,781,182,266
Fas (+) cellsPearson ,040−,180,070−,217−,268,234,241,037,000,103,044−,011,119,157
P,866,448,769,359,254,402,386,879,999,674,857,965,686,591
Fas densityPearson −,303−,109−,324−,018−,025,258,317−,243−,047−,327,009,001,124,229
P,254,688,221,947,926,395,291,383,867,234,974,997,732,524
Fasl (+) cellsPearson −,153−,369−,176−,310−,385,073,050−,230−,357−,283−,309,089−,081−,028
P,520,110,459,184,094,796,861,343,133,240,198,718,782,924
Fasl densityPearson ,195,172,223,195−,077,215,152,102,053,072−,021−,171,548,431
P,486,541,424,487,784,501,637,729,858,807,942,558,127,247

: statistically significant.
FVC: forced vital capacity, FEV1: forced expiratory volume in one second, DLCO: diffusing capacity for carbon monoxide, a: after six months of treatment.